Toll-like receptor ligands energize peptide vaccines through multiple paths

Research output: Contribution to journalReview article

42 Scopus citations

Abstract

The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.

Original languageEnglish (US)
Pages (from-to)7945-7947
Number of pages3
JournalCancer Research
Volume67
Issue number17
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this